Spots Global Cancer Trial Database for hdac inhibitor
Every month we try and update this database with for hdac inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) | NCT02759601 | Hepatocellular ... | Tefinostat | 18 Years - | Queen Mary University of London | |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT03373019 | Chidamide Lymphoma, B-Cel... Lymphoma, Large... Neoplasm by His... Neoplasms Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Cyclophosphamid... Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor | Chidamide combi... | 18 Years - 75 Years | Fudan University | |
| Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT00865969 | Peripheral T-ce... | Belinostat | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) | NCT02759601 | Hepatocellular ... | Tefinostat | 18 Years - | Queen Mary University of London | |
| A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | NCT00621244 | Lymphoma Leukemia Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma | NCT00412997 | Tumors Cutaneous T-Cel... | LBH589 | 20 Years - | Novartis | |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | NCT02836548 | Melanoma Skin Neoplasms | Vorinostat | - | The Netherlands Cancer Institute | |
| A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | NCT00621244 | Lymphoma Leukemia Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment | NCT03515915 | Patients With R... | 18 Years - | University Hospital, Montpellier | ||
| Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | NCT00699296 | Cutaneous T-Cel... Leukemia-Lympho... | Panobinostat (L... | 20 Years - | Novartis | |
| Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | NCT00699296 | Cutaneous T-Cel... Leukemia-Lympho... | Panobinostat (L... | 20 Years - | Novartis | |
| Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | NCT00511576 | Breast Cancer Lung Cancer Pulmonary Cance... Non-Small-Cell ... Prostate Cancer Prostatic Cance... Gastric Cancer Stomach Cancer | MGCD0103 & Doce... | 18 Years - | Mirati Therapeutics Inc. | |
| Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment | NCT03515915 | Patients With R... | 18 Years - | University Hospital, Montpellier | ||
| A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | NCT00567879 | Breast Cancer | Panobinostat Trastuzumab | 18 Years - | Novartis | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | NCT00788931 | HER-2 Positive ... Metastatic Brea... | IV LBH589 Oral LBH589 trastuzumab paclitaxel | 18 Years - | Novartis | |
| Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) | NCT02759601 | Hepatocellular ... | Tefinostat | 18 Years - | Queen Mary University of London | |
| A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma | NCT03710915 | Multiple Myelom... Relapsed and Re... | HG146 | 18 Years - 75 Years | HitGen Inc. | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer | NCT00772798 | Ovarian Cancer | Paclitaxel, Car... | 18 Years - | Herlev Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
